A detailed history of Abrdn PLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Abrdn PLC holds 363,679 shares of DNLI stock, worth $9.76 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
363,679
Previous 573,035 36.53%
Holding current value
$9.76 Million
Previous $13.3 Million 20.38%
% of portfolio
0.02%
Previous 0.03%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$20.96 - $31.05 $4.39 Million - $6.5 Million
-209,356 Reduced 36.53%
363,679 $10.6 Million
Q2 2024

Aug 09, 2024

BUY
$14.96 - $23.22 $852,959 - $1.32 Million
57,016 Added 11.05%
573,035 $13.3 Million
Q1 2024

May 08, 2024

BUY
$15.83 - $23.35 $3.03 Million - $4.46 Million
191,190 Added 58.86%
516,019 $10.6 Million
Q4 2023

Jan 31, 2024

BUY
$16.2 - $23.18 $5.26 Million - $7.53 Million
324,829 New
324,829 $6.97 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.6B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Abrdn PLC Portfolio

Follow Abrdn PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

News

Stay updated on Abrdn PLC with notifications on news.